Targeting B cells and plasma cells in autoimmune diseases
- 1Universität zu Lübeck, Germany
Success with B cell depletion using rituximab has proven the concept that B lineage cells represent a valid target for the treatment of autoimmune diseases and has promoted the development of other B cell targeting agents. Current results confirmed that B cell depletion could be beneficial in various autoimmune disorders, but also showed that it could worsen the disease course in some patients. These finding may stress the fact that B lineage cells do not only produce pathogenic autoantibodies, but can also significantly contribute to control of inflammation. In this review, we will discuss the multiple pro-and anti-inflammatory roles B lineage cells play in autoimmune diseases in the context of recent findings using B lineage targeting therapies.
Keywords: B cells, IL-10+ B cell, Autoantibodies, autoimmune disease, Rheumatoid arthritis, rituximab, Bortezomib
Received: 17 Dec 2017;
Accepted: 05 Apr 2018.
Edited by:Duncan Howie, University of Oxford, United Kingdom
Reviewed by:Raymond J. Steptoe, The University of Queensland, Australia
Adriana Gruppi, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI CONICET), Argentina
Andrew L. Snow, Uniformed Services University of the Health Sciences, United States
Copyright: © 2018 Hofmann, Clauder and Manz. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: PhD. Katharina Hofmann, Universität zu Lübeck, Lübeck, Germany, firstname.lastname@example.org